Company Description
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.
In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy.
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020.
The company was founded in 2018 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | George Magrath |
Contact Details
Address: 8 Davis Drive, Suite 220 Durham, North Carolina 27713 United States | |
| Phone | 984 884 6030 |
| Website | opusgtx.com |
Stock Details
| Ticker Symbol | IRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1228627 |
| ISIN Number | US67577R1023 |
| Employer ID | 11-3516358 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. George Magrath M.B.A., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Benjamin R. Yerxa Ph.D. | President and Director |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific and Development Officer |
| Robert E. Gagnon | Chief Financial Officer and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2026 | 8-K | Current Report |
| Apr 7, 2026 | 8-K | Current Report |
| Mar 23, 2026 | ARS | Filing |
| Mar 23, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 16, 2026 | 144 | Filing |
| Mar 13, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 12, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 8-K | Current Report |